Press Release

Auspex Pharma to be Acquired by Teva for $3.5 Billion

March 31, 2015

Palo Alto – March 31, 2015 – Cooley is advising Auspex Pharmaceuticals, Inc. on its acquisition by Teva Pharmaceutical Industries Ltd. for approximately $3.5 billion. The transaction is expected to close in mid-2015.

Auspex Pharmaceuticals is a late-clinical stage biopharmaceutical company dedicated to developing innovative medicines for hyperkinetic movement disorders and other rare diseases. Auspex employs its proprietary technology to create patent-protected, new chemical entities from known, clinically proven therapies. The company's lead product, SD-809 (deutetrabenazine), is in final stages of development for the treatment of chorea associated with Huntington's disease, a neurodegenerative movement disorder that impacts cognition, behavior and movements.

Teva Pharmaceutical is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world's largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area.

The Cooley corporate team advising Auspex is led by partner and head of the firm's M&A practice, Barbara Borden, and includes partners Rama Padmanabhan and Ken Rollins, special counsel James Pennington, and associates Nicole van de Leuv, Matthew Silverman and Sunny Chang.

Critical support for the transaction is being provided by partner Kay Chandler (life sciences transactions); partner Mark Windfeld-Hansen and associate Todd Gluth (tax); partner Howard Morse and associate David Burns (antitrust); partner Natasha Leskovsek and associate Sarah diFrancesca (health care and life sciences regulatory); and associate Megan Arthur (compensation and benefits).

About Cooley LLP

Cooley's lawyers solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, often where innovation meets the law.

Cooley has 850 lawyers across 12 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.